Potassium Carbonate → 4-[2-(3-Fluoro-pyridin-2-yl)-imidazol-1-ylmethyl]-2-methyl-5-propyl-pyrimidine
反応式
Cl[C:2]1[C:7]([CH2:8][CH2:9][CH3:10])=[C:6]([CH2:11][N:12]2[CH:16]=[CH:15][N:14]=[C:13]2[C:17]2[C:22]([F:23])=[CH:21][CH:20]=[CH:19][N:18]=2)[N:5]=[C:4]([CH3:24])[N:3]=1.C([O-])([O-])=O.[K+].[K+]>C(O)C.[Pd]>[F:23][C:22]1[C:17]([C:13]2[N:12]([CH2:11][C:6]3[C:7]([CH2:8][CH2:9][CH3:10])=[CH:2][N:3]=[C:4]([CH3:24])[N:5]=3)[CH:16]=[CH:15][N:14]=2)=[N:18][CH:19]=[CH:20][CH:21]=1参加物
5
実験手順
A mixture of 4-chloro-6-[2-(3-fluoro-pyridin-2-yl)-imidazol-1-ylmethyl]-2-methyl-5-propyl-pyrimidine (55.3 mg, 0.16 mmol), K2CO3 (30 mg) and Pd—C (10%, 6 mg) in ethanol is stirred at room temperature under H2 (H2 balloon) over night. After filtration, the solvent is removed and the residue is purified by preparative TLC to give the title compound. 1H NMR (CDCl3) 8.34 (s, 1H), 8.31-8.33 (m, 1H), 7.50-7.55 (m, 1H), 7.23-7.28 (m, 2H), 7.10 (s, 1H), 5.73 (s, 2H), 2.54 (s, 3H), 2.48 (t, 2H), 1.44-1.53 (m, 2H), 0.89 (t, 3H).
後処理
- filtrationAfter filtration
- customthe solvent is removed
- customthe residue is purified by preparative TLC
出典と根拠
- ORDレコード
- ord-e9dc5277bea043f58aabcb132b1727f5
- 出典データセット
- uspto-grants-2005_10
- 特許番号
- US06951864B2
反応ノート
読み込み中…